On January 9th, the German entrepreneur Nadine Rebel formulated an open letter to BioNTech that received much attention, which was read around 150,000 times in Report 24 alone: ”Big questions to Biontech: why is there a Cov-19 vaccination in the 2019 annual report?” Billion company: In essence, if you have any questions, you should contact your doctor or pharmacist.
The key question, “How was it possible for your company to develop a therapeutic that had already completed the preclinical test phase at the end of 2019, when the virus only appeared in December 2019?‘ was not answered at all and not mentioned at all. This is exciting in that many of our readers pointed out to us that the question could be pretty easily dismissed if you wanted to. Since the annual report was only created in 2020, it would certainly be possible and not unusual to process more recent findings from 2020 in it. BioNTech did not give this answer, although it would be very easy to give.
Rather, BioNTech explains:
BioNTech complies with local laws. Accordingly, we are prohibited from advising patients individually
and we may only provide the information specified in the drug information sheet or in
can be found in the package insert. Regarding your request, you will find information in the
Information for professionals and in the leaflet that you find below
(https://praxis.comirnaty.de/de/public/download-center.html) Find. More information about
Comirnaty see (https://mrnaverstehen.biontech.de/).
We recommend that you speak to your doctor or pharmacist who will be able to advise you better.
If your doctor has further questions, he/she can contact you, quoting case number 1959
and at +49 6131 9084-0 and/or [email protected] to the Department of Medical
Information (Medical Information) contact.
Comirnaty (the COVID-19 mRNA vaccine (nucleoside modified)) is used for active immunization
Used to prevent COVID-19 caused by the SARS-CoV-2 virus. The application of
Vaccine should be done in accordance with official recommendations. About
The individual information on the preparation can be found in the relevant specialist information here
is available: https://www.ema.europa.eu/en/documents/product-information/comirnaty-eparproduct-information_de.pdf
One might think that it would be rather impudent to send a person to the doctor or pharmacist asking questions about the business report, the nature and difference of immunotherapy versus vaccination, and the trials and testing phases.
The fact that BioNTech refers to a doctor or pharmacist should set alarm bells ringing for all doctors and pharmacists. When it comes to liability for side effects, consequential damages and fatalities, these professions will also be brushed aside.